Chronic demyelination is a pathological hallmark of multiple sclerosis (MS). Only a minority of MS lesions remyelinates completely. Enhancing remyelination is, therefore, a major aim of future MS therapies. Here we took a novel approach to identify factors that may inhibit or support endogenous remyelination in MS. We dissected remyelinated, demyelinated active, and demyelinated inactive white matter MS lesions, and compared transcript levels of myelination and inflammation-related genes using quantitative PCR on customized TaqMan Low Density Arrays. In remyelinated lesions, fibroblast growth factor (FGF) 1 was the most abundant of all analyzed myelination-regulating factors, showed a trend towards higher expression as compared to demyelina...
Multiple sclerosis (MS) is a chronic disease of the central nervous system characterized by local lo...
OBJECTIVE:Here, we applied a multi-omics approach (i) to examine molecular pathways related to de- a...
Remyelination is a central aspect of new multiple sclerosis (MS) therapies, in which one aims to all...
Chronic demyelination is a pathological hallmark of multiple sclerosis (MS). Only a minority of MS l...
Chronic demyelination is a pathological hallmark of multiple sclerosis (MS). Only a minority of MS l...
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervo...
The failure of remyelination in multiple sclerosis is largely unexplained. Lindner et al. report tha...
Fibroblast growth factor (FGF) signaling contributes to failure of remyelination in multiple scleros...
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system. In around ...
Fibroblast growth factor (FGF) signaling is involved in the pathogenesis of multiple sclerosis (MS)....
In multiple sclerosis, endogenous oligodendrocyte precursor cells (OPCs) attempt to remyelinate area...
Central nervous system remyelination by oligodendrocyte progenitor cells (OPCs) ultimately fails in ...
Remyelination, the ability of oligodendrocytes to extend myelin sheaths to wrap demyelinated axons, ...
Why myelin repair greatly fails in multiple sclerosis (MS) is unclear. The insulin-like growth facto...
AbstractMultiple sclerosis is a common demyelinating disease that worsens over the course of disease...
Multiple sclerosis (MS) is a chronic disease of the central nervous system characterized by local lo...
OBJECTIVE:Here, we applied a multi-omics approach (i) to examine molecular pathways related to de- a...
Remyelination is a central aspect of new multiple sclerosis (MS) therapies, in which one aims to all...
Chronic demyelination is a pathological hallmark of multiple sclerosis (MS). Only a minority of MS l...
Chronic demyelination is a pathological hallmark of multiple sclerosis (MS). Only a minority of MS l...
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervo...
The failure of remyelination in multiple sclerosis is largely unexplained. Lindner et al. report tha...
Fibroblast growth factor (FGF) signaling contributes to failure of remyelination in multiple scleros...
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system. In around ...
Fibroblast growth factor (FGF) signaling is involved in the pathogenesis of multiple sclerosis (MS)....
In multiple sclerosis, endogenous oligodendrocyte precursor cells (OPCs) attempt to remyelinate area...
Central nervous system remyelination by oligodendrocyte progenitor cells (OPCs) ultimately fails in ...
Remyelination, the ability of oligodendrocytes to extend myelin sheaths to wrap demyelinated axons, ...
Why myelin repair greatly fails in multiple sclerosis (MS) is unclear. The insulin-like growth facto...
AbstractMultiple sclerosis is a common demyelinating disease that worsens over the course of disease...
Multiple sclerosis (MS) is a chronic disease of the central nervous system characterized by local lo...
OBJECTIVE:Here, we applied a multi-omics approach (i) to examine molecular pathways related to de- a...
Remyelination is a central aspect of new multiple sclerosis (MS) therapies, in which one aims to all...